Cytek Biosciences: With Growth, Low Debt, And A Positive Long-Term Outlook, Is It Undervalued?

I rate Cytek Biosciences (NASDAQ: CTKB ) with a Buy rating. I think the net losses that the company has reported since mid-2022 do not correspond with the 79.82% plunge in its stock price. Cytek hasDaniel Mellado is an economist from Carabobo University with a Master's Degree in Statistics from Simon Bolivar University, both obtained in Venezuela.Daniel worked analyzing the agricultural commodity market and the financial investment portfolio for an agribusiness group. Then, he managed two teams, one in trad ...